JP6276378B2 - ヒストンデメチラーゼ阻害剤 - Google Patents
ヒストンデメチラーゼ阻害剤 Download PDFInfo
- Publication number
- JP6276378B2 JP6276378B2 JP2016502219A JP2016502219A JP6276378B2 JP 6276378 B2 JP6276378 B2 JP 6276378B2 JP 2016502219 A JP2016502219 A JP 2016502219A JP 2016502219 A JP2016502219 A JP 2016502219A JP 6276378 B2 JP6276378 B2 JP 6276378B2
- Authority
- JP
- Japan
- Prior art keywords
- pyridine
- imidazol
- methyl
- preparation
- carbonitrile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 C[n]1c(-c2ccc(C3(CC3)C(F)(F)F)cc2)c(-c2nccc(C(*)=O)c2)nc1 Chemical compound C[n]1c(-c2ccc(C3(CC3)C(F)(F)F)cc2)c(-c2nccc(C(*)=O)c2)nc1 0.000 description 6
- QKLMRCKCBNWKDR-PZWSPEBMSA-N CC/C=C\[C@@H]1C(C(C2=CC=CC3=C[C@@H]23)(c2ccccc2)NCCN/C=C(/C(/C)=N/CC)\N)=C1 Chemical compound CC/C=C\[C@@H]1C(C(C2=CC=CC3=C[C@@H]23)(c2ccccc2)NCCN/C=C(/C(/C)=N/CC)\N)=C1 QKLMRCKCBNWKDR-PZWSPEBMSA-N 0.000 description 1
- MLEIKIABJFPWAE-UHFFFAOYSA-N CC[n]1cnc(-c2nccc(C#N)c2)c1 Chemical compound CC[n]1cnc(-c2nccc(C#N)c2)c1 MLEIKIABJFPWAE-UHFFFAOYSA-N 0.000 description 1
- MFMARIOXNZAIHE-UHFFFAOYSA-N CCc1ccccc1CC[n]1cnc(-c2cc(C(NC)=O)ccn2)c1 Chemical compound CCc1ccccc1CC[n]1cnc(-c2cc(C(NC)=O)ccn2)c1 MFMARIOXNZAIHE-UHFFFAOYSA-N 0.000 description 1
- IPBMKTJPRLOJDL-UHFFFAOYSA-N CN(C)CCC[n]1cnc(-c2nccc(C#N)c2)c1 Chemical compound CN(C)CCC[n]1cnc(-c2nccc(C#N)c2)c1 IPBMKTJPRLOJDL-UHFFFAOYSA-N 0.000 description 1
- QLURSABJFDGSCH-UHFFFAOYSA-N CN(CC[n]1cnc(-c2cc(C(OC)=O)ccn2)c1)Cc1ccccc1 Chemical compound CN(CC[n]1cnc(-c2cc(C(OC)=O)ccn2)c1)Cc1ccccc1 QLURSABJFDGSCH-UHFFFAOYSA-N 0.000 description 1
- WIGJIJYNPCKRAK-UHFFFAOYSA-N COC(c1cc(-c2c[n](Cc3cc(-c4ccccc4)ccc3)cn2)ncc1)=O Chemical compound COC(c1cc(-c2c[n](Cc3cc(-c4ccccc4)ccc3)cn2)ncc1)=O WIGJIJYNPCKRAK-UHFFFAOYSA-N 0.000 description 1
- AYQLIWPLWCHQJV-UHFFFAOYSA-N COc1c(CC[n]2cnc(C3NC=CC(C(O)=O)=C3)c2)cccc1 Chemical compound COc1c(CC[n]2cnc(C3NC=CC(C(O)=O)=C3)c2)cccc1 AYQLIWPLWCHQJV-UHFFFAOYSA-N 0.000 description 1
- BCSPEHKEKVRJOE-UHFFFAOYSA-N C[n]1c(-c(c(OCC2CC2)c2)ccc2F)c(-c2cc(C#N)ccn2)nc1 Chemical compound C[n]1c(-c(c(OCC2CC2)c2)ccc2F)c(-c2cc(C#N)ccn2)nc1 BCSPEHKEKVRJOE-UHFFFAOYSA-N 0.000 description 1
- RYHMPYHFLUZIAQ-UHFFFAOYSA-N C[n]1c(-c(cc2)ccc2N2CCCC2)c(-c2nccc(C(O)=O)c2)nc1 Chemical compound C[n]1c(-c(cc2)ccc2N2CCCC2)c(-c2nccc(C(O)=O)c2)nc1 RYHMPYHFLUZIAQ-UHFFFAOYSA-N 0.000 description 1
- OTBZGJHFGXDSHF-UHFFFAOYSA-N C[n]1c(-c(cc2)ccc2OC(F)(F)F)c(-c2nccc(C(O)=O)c2)nc1 Chemical compound C[n]1c(-c(cc2)ccc2OC(F)(F)F)c(-c2nccc(C(O)=O)c2)nc1 OTBZGJHFGXDSHF-UHFFFAOYSA-N 0.000 description 1
- LXCBCJKGQNJVQT-UHFFFAOYSA-N C[n]1c(-c(cc2)ccc2OCC2CC2)c(-c2nccc(C(OC)=O)c2)nc1 Chemical compound C[n]1c(-c(cc2)ccc2OCC2CC2)c(-c2nccc(C(OC)=O)c2)nc1 LXCBCJKGQNJVQT-UHFFFAOYSA-N 0.000 description 1
- RGGHHODGOGDPOE-UHFFFAOYSA-N C[n]1c(-c(cc2F)ccc2Cl)c(-c2nccc(C#N)c2)nc1 Chemical compound C[n]1c(-c(cc2F)ccc2Cl)c(-c2nccc(C#N)c2)nc1 RGGHHODGOGDPOE-UHFFFAOYSA-N 0.000 description 1
- MYEKGNIACAPRJV-UHFFFAOYSA-N C[n]1c(-c(cc2OCc3ccccc3)ccc2Cl)c(-c2nccc(C#N)c2)nc1 Chemical compound C[n]1c(-c(cc2OCc3ccccc3)ccc2Cl)c(-c2nccc(C#N)c2)nc1 MYEKGNIACAPRJV-UHFFFAOYSA-N 0.000 description 1
- ZAXOFLKXTQAQTR-UHFFFAOYSA-N C[n]1c(-c2ccc(cc[nH]3)c3c2)c(-c2nccc(C#N)c2)nc1 Chemical compound C[n]1c(-c2ccc(cc[nH]3)c3c2)c(-c2nccc(C#N)c2)nc1 ZAXOFLKXTQAQTR-UHFFFAOYSA-N 0.000 description 1
- INLYKPMFVOTAJW-UHFFFAOYSA-N C[n]1c(Br)c(-c2nccc(C(N=O)=O)c2)nc1 Chemical compound C[n]1c(Br)c(-c2nccc(C(N=O)=O)c2)nc1 INLYKPMFVOTAJW-UHFFFAOYSA-N 0.000 description 1
- OMRDLSVRGDLQSA-UHFFFAOYSA-N FC(C1C(Cl)=C(C[n]2cnc(-c3nccc(-c4n[nH]nn4)c3)c2)C=CC1)(F)F Chemical compound FC(C1C(Cl)=C(C[n]2cnc(-c3nccc(-c4n[nH]nn4)c3)c2)C=CC1)(F)F OMRDLSVRGDLQSA-UHFFFAOYSA-N 0.000 description 1
- OHROAERJATZXPV-UHFFFAOYSA-N N=C(C(C1)C=CN=C1c1c[n](C2CNCC2)cn1)O Chemical compound N=C(C(C1)C=CN=C1c1c[n](C2CNCC2)cn1)O OHROAERJATZXPV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361783563P | 2013-03-14 | 2013-03-14 | |
| US61/783,563 | 2013-03-14 | ||
| PCT/US2014/026710 WO2014151945A1 (en) | 2013-03-14 | 2014-03-13 | Histone demethylase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016514159A JP2016514159A (ja) | 2016-05-19 |
| JP2016514159A5 JP2016514159A5 (enExample) | 2017-02-16 |
| JP6276378B2 true JP6276378B2 (ja) | 2018-02-07 |
Family
ID=51529949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016502219A Expired - Fee Related JP6276378B2 (ja) | 2013-03-14 | 2014-03-13 | ヒストンデメチラーゼ阻害剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (5) | US9133166B2 (enExample) |
| EP (1) | EP2969007B1 (enExample) |
| JP (1) | JP6276378B2 (enExample) |
| AU (1) | AU2014236711A1 (enExample) |
| CA (1) | CA2903081A1 (enExample) |
| ES (1) | ES2731773T3 (enExample) |
| WO (1) | WO2014151945A1 (enExample) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9133166B2 (en) | 2013-03-14 | 2015-09-15 | Quanticel Pharmaceuticals, Inc. | Histone demethylase inhibitors |
| CA2954060A1 (en) | 2014-07-03 | 2016-01-07 | Celgene Quanticel Research, Inc. | Inhibitors of lysine specific demethylase-1 |
| US9896436B2 (en) | 2014-09-16 | 2018-02-20 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| EA201790502A1 (ru) * | 2014-09-16 | 2017-10-31 | Селджен Квонтисел Рисёрч, Инк. | Ингибиторы гистоновых диметилаз |
| JP2016089002A (ja) * | 2014-10-31 | 2016-05-23 | 出光興産株式会社 | ベンゾフラノチオフェン骨格を有するモノマー及びポリマー、及びそのポリマーを用いた有機薄膜太陽電池材料 |
| JP6889661B2 (ja) * | 2015-01-09 | 2021-06-18 | ジェネンテック， インコーポレイテッド | ４，５−ジヒドロイミダゾール誘導体およびヒストンジメチラーゼ（ｋｄｍ２ｂ）インヒビターとしてのその使用 |
| WO2016210292A1 (en) | 2015-06-25 | 2016-12-29 | Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance |
| US20190055212A1 (en) * | 2016-02-16 | 2019-02-21 | Stephen Gwaltney | Histone demethylase inhibitors |
| WO2017161001A1 (en) | 2016-03-15 | 2017-09-21 | Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion |
| EP3436445B1 (en) * | 2016-03-15 | 2023-09-06 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| US10150754B2 (en) | 2016-04-19 | 2018-12-11 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| EP3246330A1 (en) | 2016-05-18 | 2017-11-22 | Istituto Europeo di Oncologia S.r.l. | Imidazoles as histone demethylase inhibitors |
| ES2969239T3 (es) | 2016-05-27 | 2024-05-17 | Gilead Sciences Inc | Combinación de ledipasvir y sofosbuvir para su uso en el tratamiento de infecciones por el virus de la hepatitis B en humanos |
| BR102017010009A2 (pt) | 2016-05-27 | 2017-12-12 | Gilead Sciences, Inc. | Compounds for the treatment of hepatitis b virus infection |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| ES2826748T3 (es) | 2016-09-02 | 2021-05-19 | Gilead Sciences Inc | Derivados de 4,6-diamino-pirido[3,2-d]pirimidina como moduladores de receptores de tipo Toll |
| KR102268448B1 (ko) | 2016-09-02 | 2021-06-22 | 길리애드 사이언시즈, 인코포레이티드 | 톨 유사 수용체 조정제 화합물 |
| MA46535A (fr) | 2016-10-14 | 2019-08-21 | Prec Biosciences Inc | Méganucléases modifiées spécifiques de séquences de reconnaissance dans le génome du virus de l'hépatite b |
| CN106543092B (zh) * | 2016-10-14 | 2019-05-17 | 华东师范大学 | 1,5-二芳香基-1,2,4-三氮唑类化合物及其制药用途 |
| TWI868958B (zh) | 2017-01-31 | 2025-01-01 | 美商基利科學股份有限公司 | 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型 |
| JOP20180008A1 (ar) | 2017-02-02 | 2019-01-30 | Gilead Sciences Inc | مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b |
| JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
| EP3728283B1 (en) | 2017-12-20 | 2023-11-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| CN111511754B (zh) | 2017-12-20 | 2023-09-12 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸 |
| WO2019160882A1 (en) | 2018-02-13 | 2019-08-22 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| KR102526964B1 (ko) | 2018-02-26 | 2023-04-28 | 길리애드 사이언시즈, 인코포레이티드 | Hbv 복제 억제제로서의 치환된 피롤리진 화합물 |
| WO2019195181A1 (en) | 2018-04-05 | 2019-10-10 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TW201945388A (zh) | 2018-04-12 | 2019-12-01 | 美商精密生物科學公司 | 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶 |
| WO2019204609A1 (en) | 2018-04-19 | 2019-10-24 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
| WO2019236766A1 (en) | 2018-06-06 | 2019-12-12 | Ideaya Biosciences, Inc. | Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using lactam compounds |
| BR112020026746A2 (pt) | 2018-07-13 | 2021-03-30 | Gilead Sciences, Inc. | Composto, composição farmacêutica, métodos para inibir pd-1, pd-l1 e/ou a interação de pd-1/pd-l1 e para tratar câncer, e, kit para tratar ou prevenir câncer ou uma doença ou condição. |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| CN112955435B (zh) | 2018-10-24 | 2024-09-06 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
| KR102658602B1 (ko) | 2018-10-31 | 2024-04-19 | 길리애드 사이언시즈, 인코포레이티드 | Hpk1 억제 활성을 갖는 치환된 6-아자벤즈이미다졸 화합물 |
| FI3873903T3 (fi) | 2018-10-31 | 2024-03-26 | Gilead Sciences Inc | Substituoituja 6-azabentsiimidatsoliyhdisteitä HPK1-inhibiittoreina |
| EP3934757B1 (en) | 2019-03-07 | 2023-02-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
| EP3935065A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| CA3129011C (en) | 2019-03-07 | 2023-12-19 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI826690B (zh) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | 經取代之烯吲哚酮化物及其用途 |
| JP7237311B2 (ja) * | 2019-06-06 | 2023-03-13 | 京都府公立大学法人 | 化合物、医薬組成物、ｋｄｍ５ｃ阻害剤及び抗うつ剤 |
| MX2021015452A (es) | 2019-06-25 | 2022-02-11 | Gilead Sciences Inc | Proteinas de fusion flt3l-fc y metodos de uso. |
| WO2021011891A1 (en) | 2019-07-18 | 2021-01-21 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
| WO2021034804A1 (en) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| KR20220074917A (ko) | 2019-09-30 | 2022-06-03 | 길리애드 사이언시즈, 인코포레이티드 | Hbv 백신 및 hbv를 치료하는 방법 |
| DK4069729T3 (da) | 2019-12-06 | 2025-04-07 | Prec Biosciences Inc | Optimerede, modificerede meganukleaser med specificitet for en genkendelsessekvens i hepatitis b-virusgenomet |
| AR121620A1 (es) | 2020-03-20 | 2022-06-22 | Gilead Sciences Inc | Profármacos de nucleósidos 4-c-sustituidos-2-halo-2-deoxiadenosina y métodos de preparación y uso de los mismos |
| JP7712352B2 (ja) | 2020-08-07 | 2025-07-23 | ギリアード サイエンシーズ， インコーポレイテッド | ホスホンアミドヌクレオチド類似体のプロドラッグ及びその薬学的使用 |
| TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| EP4337223A1 (en) | 2021-05-13 | 2024-03-20 | Gilead Sciences, Inc. | Combination of a tlr8 modulating compound and anti-hbv sirna therapeutics |
| AU2022299051B2 (en) | 2021-06-23 | 2025-03-13 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| KR20240025616A (ko) | 2021-06-23 | 2024-02-27 | 길리애드 사이언시즈, 인코포레이티드 | 다이아실글리세롤 키나제 조절 화합물 |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| AU2022298639C1 (en) | 2021-06-23 | 2025-07-17 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| KR20250099113A (ko) | 2022-09-09 | 2025-07-01 | 이노보 테라퓨틱스 인코포레이티드 | CK1α 및 DUAL CK1α/GSPT1 분해 화합물 |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| US20250345389A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3127900A (en) | 1998-12-23 | 2000-07-31 | Du Pont Pharmaceuticals Company | Thrombin or factor xa inhibitors |
| AU3980602A (en) | 2000-10-26 | 2002-06-03 | Tularik Inc | Antiinflammation agents |
| US20040127733A1 (en) | 2002-10-31 | 2004-07-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New beta-agonists, processes for preparing them and their use as pharmaceutical compositions |
| DE102004021779A1 (de) | 2004-04-30 | 2005-11-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| JP2009519998A (ja) | 2005-12-19 | 2009-05-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | アミノアルコール誘導体の過活動膀胱の治療の為の使用 |
| JP4388997B2 (ja) * | 2006-09-05 | 2009-12-24 | 協和発酵キリン株式会社 | イミダゾール誘導体 |
| AU2008242720A1 (en) * | 2007-04-20 | 2008-10-30 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases |
| GB0818907D0 (en) * | 2008-10-15 | 2008-11-19 | Isis Innovation | Histone lysine demethylase inhibitors |
| US20120101099A1 (en) * | 2009-07-07 | 2012-04-26 | Anthem Biosciences Private Limited | Histone deacetylase inhibitors |
| CN102695708B (zh) | 2009-11-10 | 2014-10-15 | 辉瑞大药厂 | N1-吡唑并螺酮乙酰辅酶a羧化酶抑制剂 |
| WO2011089995A1 (ja) * | 2010-01-21 | 2011-07-28 | 公立大学法人名古屋市立大学 | ヒドロキサム酸誘導体及びそれを用いたｈｄａｃ８阻害剤 |
| GB201112607D0 (en) * | 2011-07-22 | 2011-09-07 | Glaxo Group Ltd | Novel compounds |
| CN102775368B (zh) * | 2011-05-10 | 2016-08-17 | 上海驺虞医药科技有限公司 | 一类噻唑类化合物及其制备方法和用途 |
| US9133166B2 (en) * | 2013-03-14 | 2015-09-15 | Quanticel Pharmaceuticals, Inc. | Histone demethylase inhibitors |
| EA201790502A1 (ru) | 2014-09-16 | 2017-10-31 | Селджен Квонтисел Рисёрч, Инк. | Ингибиторы гистоновых диметилаз |
-
2014
- 2014-03-13 US US14/210,006 patent/US9133166B2/en active Active
- 2014-03-13 US US14/774,338 patent/US9527829B2/en active Active
- 2014-03-13 JP JP2016502219A patent/JP6276378B2/ja not_active Expired - Fee Related
- 2014-03-13 WO PCT/US2014/026710 patent/WO2014151945A1/en not_active Ceased
- 2014-03-13 CA CA2903081A patent/CA2903081A1/en not_active Abandoned
- 2014-03-13 ES ES14767499T patent/ES2731773T3/es active Active
- 2014-03-13 EP EP14767499.8A patent/EP2969007B1/en active Active
- 2014-03-13 AU AU2014236711A patent/AU2014236711A1/en not_active Abandoned
-
2015
- 2015-09-11 US US14/852,079 patent/US9701657B2/en active Active
-
2016
- 2016-11-17 US US15/354,044 patent/US9963441B2/en active Active
-
2017
- 2017-06-07 US US15/616,319 patent/US10273222B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US10273222B2 (en) | 2019-04-30 |
| US20170066739A1 (en) | 2017-03-09 |
| ES2731773T3 (es) | 2019-11-19 |
| CA2903081A1 (en) | 2014-09-25 |
| AU2014236711A1 (en) | 2015-09-17 |
| EP2969007A1 (en) | 2016-01-20 |
| US9527829B2 (en) | 2016-12-27 |
| US20170334879A1 (en) | 2017-11-23 |
| US9133166B2 (en) | 2015-09-15 |
| EP2969007B1 (en) | 2019-05-08 |
| US20160113914A1 (en) | 2016-04-28 |
| JP2016514159A (ja) | 2016-05-19 |
| US20160122314A1 (en) | 2016-05-05 |
| US9963441B2 (en) | 2018-05-08 |
| WO2014151945A1 (en) | 2014-09-25 |
| EP2969007A4 (en) | 2016-07-27 |
| US9701657B2 (en) | 2017-07-11 |
| US20140275084A1 (en) | 2014-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6276378B2 (ja) | ヒストンデメチラーゼ阻害剤 | |
| JP6256771B2 (ja) | ヒストンデメチラーゼ阻害剤 | |
| KR102400920B1 (ko) | 리신 특이적 데메틸라제-1의 억제제 | |
| AU2013363957A1 (en) | Histone demethylase inhibitors | |
| KR20170048590A (ko) | 히스톤 데메틸라아제 억제제 | |
| JP6970680B2 (ja) | ヒストンデメチラーゼ阻害剤 | |
| JP2017529347A (ja) | ヒストンデメチラーゼ阻害剤 | |
| US9896436B2 (en) | Histone demethylase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151026 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170107 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170309 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20171106 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20171225 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180111 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6276378 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |